Clinical Intelligence Infrastructure

DeepCare Labs

Specialist-grade addiction care, anywhere it’s needed. ATLAS extends one provider’s expertise to every staff member, every site, and every patient – so clinics can grow without hiring specialists they cannot find. Currently in early-stage development with academic and clinical partners.

Get in Touch

Stage: Early-stage development
Headquarters: Baltimore, MD
Partners: Academic & clinical

The Problem

The demand for addiction care has outgrown the specialists who deliver it.

Addiction Medicine runs on a specialist workforce that cannot scale to meet demand, without the clinical infrastructure other specialties rely on. The U.S. is losing ~200 lives a day to overdose, ~80% of people with a substance use disorder never receive treatment, and the clinics that want to grow cannot – labor costs consume up to 89% of operating expenses and there is one board-certified addiction clinician for every 8,000 patients.

~200 / day: U.S. lives lost to overdose, every day.
~80%: of people with a substance use disorder never receive treatment.
Up to89%: of operating expenses consumed by labor at clinics that want to grow.

Sources: HRSA, 2025; SAMHSA NSDUH, 2024.

DeepCare Labs is building the infrastructure to change how addiction care is scaled.

Approach

A platform purpose-built for outpatient SUD treatment.

ATLAS is built to amplify the addiction care workforce. It pairs clinical decision support and precision medicine systems with workflow automation so a clinic's existing staff can do more, guided by specialist-grade reasoning.

Engineered for 42 CFR Part 2 and HIPAA compliance from day one, ATLAS is intended to integrate with existing EHRs. Clinical validation is underway with academic partners.

Team

Built by world-leading researchers and operators in addiction medicine.

Albert Burgess-Hull, PhD

CEO & Co-Founder

Addiction scientist and applied statistician; 40+ peer-reviewed outputs.
15+ years of NIH/NIDA-funded research (NIDA postdoctoral training; Yale, Duke, NCI fellowships; PhD, University of Wisconsin–Madison).
6+ years deploying AI in production across 50+ outpatient SUD treatment sites (prior work at MATClinics and SUDx).
Sole inventor on treatment response subtyping IP.

Zifan "Ivan" Gu, MS

CSO & Co-Founder

PhD candidate in Biomedical Engineering at UT Southwestern Medical Center; MS in Biomedical Informatics from Harvard Medical School.
Member of I4SUD commercialization accelerator (2025 cohort; Johns Hopkins Carey Business School)
5+ years of health data science research spanning agentic AI decision support, multimodal clinical prediction, and biostatistical modeling.
15+ peer-reviewed and preprint outputs.
Expertise in clinician-in-the-loop LLM feedback mechanism and digital twins.

Get in Touch

Talk to the team.

For investors, clinic operators, and academic collaborators. We respond to every inquiry directly.